OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has co… Read more
OBI Pharma (4174) - Total Liabilities
Latest total liabilities as of September 2025: NT$748.70 Million TWD
Based on the latest financial reports, OBI Pharma (4174) has total liabilities worth NT$748.70 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OBI Pharma - Total Liabilities Trend (2011–2024)
This chart illustrates how OBI Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OBI Pharma Competitors by Total Liabilities
The table below lists competitors of OBI Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Desktop Metal Inc
NYSE:DM
|
USA | $201.34 Million |
|
Grupo Empresas Navieras SA
SN:NAVIERA
|
Chile | CL$992.96 Million |
|
Thomas Cook (India) Limited
NSE:THOMASCOOK
|
India | ₹51.42 Billion |
|
Honat Bancorp Inc
PINK:HONT
|
USA | $976.56 Million |
|
Maxim Power Corp
PINK:MXGFF
|
USA | $31.90 Million |
|
FREYR Battery SA
NYSE:FREY
|
USA | $1.18 Billion |
|
Pace Digitek Limited
NSE:PACEDIGITK
|
India | ₹14.40 Billion |
|
Interflex Co. Ltd
KQ:051370
|
Korea | ₩69.58 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down OBI Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OBI Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OBI Pharma (2011–2024)
The table below shows the annual total liabilities of OBI Pharma from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$833.38 Million | +28.12% |
| 2023-12-31 | NT$650.45 Million | +30.73% |
| 2022-12-31 | NT$497.57 Million | -19.22% |
| 2021-12-31 | NT$615.95 Million | +22.68% |
| 2020-12-31 | NT$502.09 Million | +9.35% |
| 2019-12-31 | NT$459.14 Million | +94.53% |
| 2018-12-31 | NT$236.03 Million | +82.04% |
| 2017-12-31 | NT$129.66 Million | -22.51% |
| 2016-12-31 | NT$167.32 Million | +31.74% |
| 2015-12-31 | NT$127.00 Million | +187.09% |
| 2014-12-31 | NT$44.24 Million | +6.71% |
| 2013-12-31 | NT$41.46 Million | -6.63% |
| 2012-12-31 | NT$44.40 Million | +211.09% |
| 2011-12-31 | NT$14.27 Million | -- |